Shares of Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) rose 5.6% during trading on Monday . The stock traded as high as $16.12 and last traded at $14.54. Approximately 39,502 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 204,829 shares. The stock had previously closed at $13.77.
Analysts Set New Price Targets
Several equities research analysts recently commented on SION shares. Stifel Nicolaus started coverage on shares of Sionna Therapeutics in a research note on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Guggenheim began coverage on shares of Sionna Therapeutics in a research note on Tuesday. They set a “buy” rating and a $45.00 price target on the stock. Finally, TD Cowen began coverage on shares of Sionna Therapeutics in a research note on Tuesday. They set a “buy” rating on the stock.
Get Our Latest Analysis on Sionna Therapeutics
Sionna Therapeutics Stock Up 4.6 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Rocket Lab’s Plunge: Buy the Dip or Watch from the Sidelines?
- The Basics of Support and Resistance
- Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Is the S&P 500 Ready to Rally? A $1.8M Bet on SPY Says Yes
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
